Beam Therapeutics (BEAM) Cash from Financing Activities (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Cash from Financing Activities data on file, last reported at $96.6 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 79.59% year-over-year to $96.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $101.3 million (down 78.82% YoY) and the FY2025 annual result came in at $478.0 million, up 6079.54% from the prior year.
• Cash from Financing Activities grew to $96.6 million in Q1 2026 per BEAM's latest filing, from $1.9 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $473.4 million in Q1 2025 and bottomed at $133000.0 in Q2 2024.
• The 5-year median for Cash from Financing Activities is $22.3 million (2022), against an average of $57.1 million.
• The widest annual swing landed in 2024, when Cash from Financing Activities plunged 99.88%; it then surged 16240.32% in 2025.
• Tracing BEAM's Cash from Financing Activities over 5 years: stood at $32.0 million in 2022, then grew by 5.31% to $33.7 million in 2023, then sank by 89.78% to $3.4 million in 2024, then slumped by 45.24% to $1.9 million in 2025, then surged by 5022.38% to $96.6 million in 2026.
• Per Business Quant, the three latest BEAM Cash from Financing Activities figures stand at $96.6 million (Q1 2026), $1.9 million (Q4 2025), and $1.7 million (Q3 2025).

Peer Comparison